ZyVersa Therapeutics Net Worth
ZyVersa Therapeutics Net Worth Breakdown | ZVSA |
ZyVersa Therapeutics Net Worth Analysis
ZyVersa Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including ZyVersa Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of ZyVersa Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform ZyVersa Therapeutics' net worth analysis. One common approach is to calculate ZyVersa Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares ZyVersa Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing ZyVersa Therapeutics' net worth. This approach calculates the present value of ZyVersa Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of ZyVersa Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate ZyVersa Therapeutics' net worth. This involves comparing ZyVersa Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into ZyVersa Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if ZyVersa Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ZyVersa Therapeutics' net worth research are outlined below:
| ZyVersa Therapeutics generated a negative expected return over the last 90 days | |
| ZyVersa Therapeutics has high historical volatility and very poor performance | |
| ZyVersa Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (98.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ZyVersa Therapeutics generates negative cash flow from operations | |
| ZyVersa Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Finizio Robert G of 132 shares of ZyVersa Therapeutics at 152.46 subject to Rule 16b-3 |
ZyVersa Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ZyVersa Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ZyVersa Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow ZyVersa Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.76 M.Market Cap |
|
Project ZyVersa Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (32.61) | (34.24) | |
| Return On Capital Employed | (1.39) | (1.32) | |
| Return On Assets | (4.00) | (4.20) | |
| Return On Equity | (10.21) | (9.70) |
When accessing ZyVersa Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures ZyVersa Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ZyVersa Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of ZyVersa Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ZyVersa Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ZyVersa Therapeutics' management manipulating its earnings.
Evaluate ZyVersa Therapeutics' management efficiency
ZyVersa Therapeutics has return on total asset (ROA) of (0.2302) % which means that it has lost $0.2302 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5959) %, meaning that it created substantial loss on money invested by shareholders. ZyVersa Therapeutics' management efficiency ratios could be used to measure how well ZyVersa Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 22, 2025, Return On Tangible Assets is expected to decline to -34.24. The current year's Return On Capital Employed is expected to grow to -1.32. At present, ZyVersa Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 36.2 M, whereas Net Tangible Assets are forecasted to decline to (11.6 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 102.22 | 97.11 | |
| Tangible Book Value Per Share | (69.91) | (73.40) | |
| Enterprise Value Over EBITDA | 0.02 | 0.02 | |
| Price Book Value Ratio | 0.07 | 0.07 | |
| Enterprise Value Multiple | 0.02 | 0.02 | |
| Price Fair Value | 0.07 | 0.07 | |
| Enterprise Value | 9.7 M | 9.2 M |
Leadership at ZyVersa Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ZyVersa Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ZyVersa Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ZyVersa Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ZyVersa Therapeutics time-series forecasting models is one of many ZyVersa Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ZyVersa Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ZyVersa Therapeutics Earnings per Share Projection vs Actual
ZyVersa Therapeutics Corporate Management
| LaBella MS | Chief RD | Profile | |
| Melda Oconnell | Senior Development | Profile | |
| Pablo MD | Chief Board | Profile | |
| MD FACC | Senior Officer | Profile | |
| Karen Cashmere | Chief Officer | Profile |
Already Invested in ZyVersa Therapeutics?
The danger of trading ZyVersa Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ZyVersa Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ZyVersa Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ZyVersa Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.